Publications by authors named "Davide Leopardo"
Objective: ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations represent fundamental predictive biomarkers for advanced non-small cell lung cancer (NSCLC) patients to ensure the best treatment choice. In this scenario, RNA-based NGS approach has emerged as an extremely useful tool for detecting these alterations. In this study, we report our NGS molecular records on ALK, ROS1, NTRK, and RET gene fusions and MET exon 14 skipping alterations detected by using a narrow RNA-based NGS panel, namely SiRe fusion.
View Article and Find Full Text PDFArticle Synopsis
- Squamous cell carcinoma of the head and neck (SCCHN) is a challenging group of cancers primarily affecting patients diagnosed at an advanced stage, typically requiring a combination of surgery, chemotherapy, and radiotherapy for treatment.
- Approximately 50% of patients experience a recurrence of the disease, and those with recurrent or metastatic SCCHN have a poor prognosis, with a median survival of around 12 months despite available treatments.
- Recent advancements in managing recurrent/metastatic SCCHN include salvage treatments like surgery and re-irradiation, which not only aim to reduce tumor size but also stimulate an immune response, highlighting the importance of a multidisciplinary approach in treating these patients.
Article Synopsis
- Thyroid nodules are common, especially in women, with most being benign and a small percentage being malignant.
- Detection methods include self-examination and neck ultrasonography, with management being challenging due to the prevalence of benign cases against the rarity of thyroid cancer.
- A standard diagnostic protocol involves initial imaging and hormone tests, followed by more invasive procedures only for suspicious nodules, with the review focusing on the genetics of thyroid cancer and available diagnostic and therapeutic options.
Article Synopsis
- Epithelial ovarian cancer is the most prevalent type, primarily affecting women over 50, and is often diagnosed at advanced stages (III or IV), leading to a poor prognosis.
- Treatment typically involves a combination of surgery and chemotherapy, which is crucial for both early and advanced cases.
- Recent years have seen the introduction of several new drugs for treatment, with ongoing research into novel targets and agents for improved outcomes.
Background: Docetaxel (DTX) and zoledronic acid (ZOL) are effective in patients with hormone resistant prostate cancer (HRPC) with bone metastases. A phase I clinical trial of metronomic administration of Zoledronic Acid AN d TaxoterE combination (ZANTE trial) in 2 different sequences was conducted in HRPC.
Results: The maximum tolerated dose was not achieved with sequence A.
Aim: To evaluate retrospectively the efficacy of rituximab plus chemotherapy in gastric diffuse large B cell lymphoma (DLBCL).
Methods: Sixty patients (median age: 58 years) with histologically confirmed gastric DLBCL treated at four Italian institutions between 2000 and 2007, were included in this analysis. Patients were selected by stage (I-IV, Lugano staging system), European Cooperative Oncology Group performance status (0-2) and treatment strategies.
Purpose: The survival of patients with hepatocellular carcinoma (HCC) has improved with advancements in various diagnostic tools and treatment modalities. Consequently, bone metastases from HCC are diagnosed more frequently. The aims of the present study was to describe the clinical features and treatment of HCC patients presenting with bone metastases.
View Article and Find Full Text PDF